About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Clinical Implications of the EMERALD Data on Treatment Outcomes in HR+/HER2- mBC
By
Robert Wesolowski
0 views
February 29, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
05:59
Lilly Medical Affairs
Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …
Feat.
J. O’Shaughnessy
Featured Video
03:57
Lilly Medical Affairs
Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …
Feat.
K. Jhaveri
Recommended
AUTOPLAY
ON
Related
Newest
25:08
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice
Feat.
S. Tolaney,
H. Rugo
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
12:14
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…
Feat.
P. Tarantino
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
05:43
Total Health
Neoadjuvant Chemo for HR+ BC: Year in Review
Feat.
C. Ma
10:34
Sara Tolaney
ASCO® 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
10:27
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…
Feat.
S. Tolaney,
H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting
Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…
Feat.
H. Rugo
06:10
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…
Feat.
S. Tolaney
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
21:31
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…
Feat.
S. Tolaney,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
33:44
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…
Feat.
S. Tolaney,
H. Rugo
27:01
Scripps Health
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
Feat.
S. Sammons
17:35
Insights from 2023 SABCS
SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…
Feat.
P. Tarantino
24:10
Keck School of Medicine of USC
CDK4/6 Inhibitors in Breast Cancer: 2024 Update
Feat.
R. O'Regan
10:09
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…
Feat.
H. Rugo
23:13
Keck School of Medicine of USC
NRG-BR009 ("OFSET") Study: Evaluating the Addition of Adju…
Feat.
T. Mamounas
05:35
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…
Feat.
S. Tolaney
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
